Cyclerion Therapeutics’ zagociguat was granted FDA orphan designation as a treatment of mitochondrial disease, according to a post to the agency’s website. Reference Link
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CYCN: